References
- Khera M, Adaikan G, Buvat J, et al. Diagnosis and treatment of testosterone deficiency: recommendations from the fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med [Internet]. 2016;13:1787–1804. [cited 2017 Dec 27]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1743609516304696
- Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab [Internet]. 2010;95:2536–2559. [cited 2016 Dec 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20525905
- Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009;55:121–130.
- Corona G, Rastrelli G, Vignozzi L, et al. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl [Internet]. 2012;14:251–259. [cited 2017 Aug 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22286862
- Buvat J, Maggi M, Guay A, et al. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med [Internet]. 2013;10:245–284. [cited 2016 Dec 14]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1743609515301120
- Bonomi M, Vezzoli V, Krausz C, et al. Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH). Eur J Endocrinol [Internet]. 2018;178:23–32. [cited 2018 Feb 7]. DOI:10.1530/EJE-17-0065.
- Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med [Internet]. 2010;363:123–135. [cited 2016 Dec 10]. DOI:10.1056/NEJMoa0911101.
- Rastrelli G, Carter EL, Ahern T, et al. Development of and recovery from secondary hypogonadism in aging men: prospective results from the EMAS. J Clin Endocrinol Metab [Internet]. 2015;100:3172–3182. [cited 2016 Dec 10]. DOI:10.1210/jc.2015-1571.
- Ahern T, Swiecicka A, Eendebak RJAH, et al. Natural history, risk factors and clinical features of primary hypogonadism in ageing men: longitudinal data from the European male ageing study. Clin Endocrinol (Oxf) [Internet]. 2016;85:891–901. [cited 2016 Dec 10]. DOI:10.1111/cen.13152.
- Tajar A, Forti G, Tw O, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab [Internet]. 2010;95:1810–1818. [cited 2016 Dec 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20173018
- Maseroli E, Corona G, Rastrelli G, et al. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med [Internet]. 2015;12:956–965. [cited 2017 Dec 27]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1743609515309905
- Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab [Internet]. 2017;102:1067–1075. [cited 2017 Dec 27]. Available from: https://academic.oup.com/jcem/article/102/3/1067/2919025/A-Perspective-on-MiddleAged-and-Older-Men-With
- Corona G, Maseroli E, Rastrelli G, et al. Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol [Internet]. 2016;41:196–210. [cited 2017 Dec 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26883937
- Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male [Internet]. 2008 [cited 2017 Dec 27];11:193–199. DOI:10.1080/13685530802468497.
- Corona G, Mannucci E, Petrone L, et al. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med [Internet]. 2007;4:789–796. [cited 2017 Dec 27]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1743609515315605
- Corona G, Maggi M. Perspective: regulatory agencies’ changes to testosterone product labeling. J Sex Med [Internet]. 2015;12:1690–1693. [cited 2017 Dec 27]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1743609515341916
- Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol [Internet]. 2013;168:829–843. [cited 2017 Dec 27]. DOI:10.1530/EJE-12-0955.
- Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr [Internet]. 2001 [cited 2017 Dec 27];21:323–341. DOI:10.1146/annurev.nutr.21.1.323.
- Corona G, Vignozzi L, Sforza A, et al. Obesity and late-onset hypogonadism. Mol Cell Endocrinol [Internet]. 2015;418(Pt 2):120–133. [cited 2017 Dec 26]. http://linkinghub.elsevier.com/retrieve/pii/S030372071500338X. Available from.
- Corona G, Bianchini S, Sforza A, et al. Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men. Hormones (Athens). [Internet]. 2015;14:569–578. [cited 2017 Dec 27]. Available from: http://www.hormones.gr/8606/article/hypogonadism-as-a-possible-link-between….html
- Dhindsa S, Furlanetto R, Vora M, et al. Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care [Internet]. 2011;34:1854–1859. [cited 2018 Feb 7]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21715518
- Kumagai H, Yoshikawa T, Zempo-Miyaki A, et al. Vigorous physical activity is associated with regular Aerobic exercise-induced increased serum testosterone levels in overweight/obese men. Horm Metab Res [Internet]. 2017 [cited 2017 Dec 27]. DOI:10.1055/s-0043-117497.
- Hayes LD, P H, Sculthorpe NF, et al. Exercise training improves free testosterone in lifelong sedentary aging men. Endocr Connect [Internet]. 2017;6:306–310. [cited 2017 Dec 27]. DOI:10.1530/EC-17-0082.
- Ari Z, Kutlu N, Uyanik BS, et al. Serum testosterone, growth hormone, and insulin-like growth factor-1 levels, mental reaction time, and maximal aerobic exercise in sedentary and long-term physically trained elderly males. Int J Neurosci [Internet]. 2004;114:623–637. [cited 2017 Dec 27]. DOI:10.1080/00207450490430499.
- Khoo J, Tian -H-H, Tan B, et al. Comparing effects of low- and high-volume moderate-intensity exercise on sexual function and testosterone in obese men. J Sex Med [Internet]. 2013;10:1823–1832. [cited 2017 Dec 27]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1743609515304173
- Kumagai H, Zempo-Miyaki A, Yoshikawa T, et al. Increased physical activity has a greater effect than reduced energy intake on lifestyle modification-induced increases in testosterone. J Clin Biochem Nutr [Internet]. 2016;58:84–89. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26798202
- Corona G, Ratrelli G, Maggi M, et al. The pharmacotherapy of male hypogonadism besides androgens. Expert Opin Pharmacother [Internet]. 2014;16:1–19. [cited 2017 Jul 15]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25523084
- Corona G, Rastrelli G, Vignozzi L, et al. Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs. 2012;17:239–259.
- Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology [Internet]. 2013;1:749–757. [cited 2017 Dec 27]. DOI:10.1111/j.2047-2927.2013.00107.x
- Ribeiro MA, Gameiro LFO, Scarano WR, et al. Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials. JBRA Assist Reprod [Internet]. 2016;20:82–88. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27244767
- Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol [Internet]. 2008;158:741–747. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18426834
- Loves S, De Jong J, van Sorge A, et al. Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. Eur J Endocrinol [Internet]. 2013;169:705–714. [cited 2017 Apr 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23949882
- Sarchielli E, Comeglio P, Squecco R, et al. Tumor necrosis factor α impairs kisspeptin signaling in human gonadotropin-releasing hormone primary neurons. J Clin Endocrinol Metab [Internet]. 2017;102:46–56. [cited 2017 Feb 13]. DOI:10.1210/jc.2016-2115.
- Liu L, Banks SM, Barnes KM, et al. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab [Internet]. 1988;67:1140–1145. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3142911
- Kaminetsky J, Hemani ML. Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency. Expert Opin Investig Drugs [Internet]. 2009 [cited 2017 Dec 27];18:1947–1955. DOI:10.1517/13543780903405608.
- Craig Jordan V, McDaniel R, Agboke F, et al. The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. Steroids [Internet]. 2014;90:3–12. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24949934
- Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet[Internet]. 1996;348:977–980. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8855852
- Riggs BL, Hartmann LC. Selective estrogen-receptor modulators––mechanisms of action and application to clinical practice. Wood AJJ, editor. N Engl J Med [Internet]. 2003 [cited 2017 Dec 27];348:618–629. DOI:10.1056/NEJMra022219.
- Rastrelli G, Corona G, Mannucci E, et al. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology [Internet]. 2014;2:794–808. [cited 2017 Jul 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25271205
- Corona G, Rastrelli G, Reisman Y, et al. The safety of available treatments of male hypogonadism in organic and functional hypogonadism. Expert Opin Drug Saf [Internet]. 2018;1–16. [cited 2018 Feb 7]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29334271
- Horton R, Shinsako J, Forsham PH. Testosterone production and metabolic clearance rates with volumes of distribution in normal adult men and women. Acta Endocrinol (Copenh) [Internet]. 1965;48:446–458. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14260997
- Corona G, Rastrelli G, Maseroli E, et al. Sexual function of the ageing male. Best Pract Res Clin Endocrinol Metab [Internet]. 2013;27:581–601. [cited 2017 Dec 27]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1521690X13000687
- Giusti G, Gonnelli P, Borrelli D, et al. Age-related secretion of androstenedione, testosterone and dihydrotestosterone by the human testis. Exp Gerontol [Internet]. 1975;10:241–245. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1204687
- Kent JR, Acone AB. Plasma testosterone levels and aging in males. Androg Norm Pathol Cond. 1966;101:31.
- Rastrelli G, Corona G, Cipriani S, et al. Sex hormone binding globulin is associated with androgen deficiency features independently of total testosterone. Clin Endocrinol (Oxf) [Internet]. 2017 [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29235134
- Nieschlag E, Nieschlag S. Testosterone deficiency: a historical perspective. Asian J Androl [Internet]. 2014;16:161–168. [cited 2017 Dec 27]. Available from: http://www.ajandrology.com/text.asp?2014/16/2/161/122358
- Corona G, Sforza A, Maggi M. Testosterone replacement therapy: long-term safety and efficacy. World J Mens Health [Internet]. 2017;35:65–76. [cited 2017 Dec 27]. DOI:10.5534/wjmh.2017.35.2.65.
- Corona G, Vignozzi L, Sforza A, et al. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health [Internet]. 2013;31:103–125. [cited 2017 Dec 27]. DOI:10.5534/wjmh.2013.31.2.103.
- Mackey MA, Conway AJ, Handelsman DJ. Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod [Internet]. 1995;10:862–865. [cited 2017 Dec 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7650133
- Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother [Internet]. 2014 [cited 2017 Dec 27];15:1903–1926. DOI:10.1517/14656566.2014.944896.
- Wang C, Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab [Internet]. 2002 [cited 2017 Dec 27];87:1462–1466. DOI:10.1210/jcem.87.4.8488.
- Swerdloff RS, Wang C. Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Baillieres Clin Endocrinol Metab [Internet]. 1998;12:501–506. [cited 2017 Dec 2017 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10332569
- Choi SK, Han SW, Kim DH, et al. Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J Urol [Internet]. 1993;150:657–660. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8326617
- Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab [Internet]. 1995 [cited 2017 Dec 27];80:3546–3552. DOI:10.1210/jcem.80.12.8530597.
- Pelusi C, Giagulli VA, Baccini M, et al. Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study. PLoS One [Internet]. 2017;12:1–16. DOI:10.1371/journal.pone.0183369
- Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: A randomized phase II clinical trial comparing topical testosterone. Fertil Steril [Internet]. 2014;102:720–727. DOI:10.1016/j.fertnstert.2014.06.004
- Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117:677–685.
- Helo S, Mahon J, Ellen J, et al. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment. BJU Int. 2017;119:171–176.
- Uebelhart B, Herrmann F, Pavo I, et al. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res [Internet]. 2004;19:1518–1524. [cited 2017 Dec 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15312253
- Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab [Internet]. 2004;89:3841–3846. [cited 2017 Dec 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15292315
- Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol [Internet]. 2010;184:1316–1321. [cited 2017 Dec 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20723926
- Leder BZ, Rohrer JL, Rubin SD, et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. 2004;89:1174–1180.
- Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int. 2005;16:1487–1494.
- Dougherty RH, Rohrer JL, Hayden D, et al. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clin Endocrinol (Oxf). 2005;62:228–235.
- Burnett-Bowie S-Am, McKay EA, Lee H, et al. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab [Internet]. 2009;94:4785–4792. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2795655&tool=pmcentrez&rendertype=abstract.
- S-Am B-B, Roupenian KC, Dere ME, et al. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) [Internet]. 2009;70:116–123.
- Herzog AG, Farina EL, Drislane FW, et al. A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism. Epilepsy Behav [Internet]. 2010;17:264–271. DOI:10.1016/j.yebeh.2009.12.003
- Dias JP, Melvin D, Simonsick EM, et al. Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial. Andrology. 2016;4:33–40.
- Dias JP, Veldhuis JD, Carlson O, et al. Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone. Metabolism. 2017;69:143–147.
- Finkelstein JS, Lee H, Burnett-Bowie S-AM, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med [Internet]. 2013;369:1011–1022. [cited 2017 Mar 26]. DOI:10.1056/NEJMoa1206168.
- Ng MKC, Liu PY, Williams AJ, et al. Prospective study of effect of androgens on serum inflammatory markers in men. Arterioscler Thromb Vasc Biol [Internet]. 2002;22:1136–1141. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12117728
- Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab [Internet]. 2002;87:3125–3135.
- Liu PY, Wishart SM, Celermajer DS, et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol [Internet]. 2003;148:55–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12534358.
- La Vignera S, Condorelli RA, Cimino L, et al. Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. Aging Male [Internet]. 2016;19:34–39. [cited 2017 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26488941
- Rastrelli G, Corona G, Tarocchi M, et al. How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Invest [Internet]. 2016;39:473–484.
- Corona G, Rastrelli G, Ricca V, et al. Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. J Sex Med [Internet]. 2013;10:1074–1089. [cited 2017 Jul 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23347078
- Isidori AM, Balercia G, Calogero AE, et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest [Internet]. 2015;38:103–112. [cited 2017 Dec 26]. DOI:10.1007/s40618-014-0155-9.
- Kelly DM, Jones TH. Testosterone and obesity. Obes Rev [Internet]. 2015 [cited 2017 Dec 26];16:581–606. DOI:10.1111/obr.12282.
- Saad F, Aversa A, Isidori AM, et al. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev [Internet]. 2012;8:131–143. [cited 2017 Dec 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22268394
- Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol [Internet]. 2017;72:1000–1011. [cited 2017 Dec 26]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0302283817302531
- Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol [Internet]. 2000;164:371–375. [cited 2017 Dec 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10893588
- Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med [Internet]. 2009;151:650–661. [cited 2017 Dec 26]. DOI:10.7326/0003-4819-151-9-200911030-00150.
- Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med [Internet]. 2014;11:1577–1592. [cited 2017 Dec 26]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1743609515307876
- Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc [Internet]. 2007;82:20–28. [cited 2017 Dec 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17285782
- Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) [Internet]. 2005;63:381–394. [cited 2017 Dec 26]. DOI:10.1111/j.1365-2265.2005.02350.x.
- Corona G, Giagulli VA, Maseroli E, et al. THERAPY OF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol [Internet]. 2016;174:R99–116. [cited 2017 Dec 26]. DOI:10.1530/EJE-15-0262.
- Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab [Internet]. 2010;95:2560–2575. [cited 2017 Dec 26]. DOI:10.1210/jc.2009-2575.
- Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc [Internet]. 2007;82:29–39. [cited 2017 Dec 26]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0025619611609646
- Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) [Internet]. 2005;63:280–293. [cited 2017 Dec 26]. DOI:10.1111/j.1365-2265.2005.02339.x.
- Tracz MJ, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. a systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab [Internet]. 2006;91:2011–2016. [cited 2017 Dec 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16720668
- MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med [Internet]. 2008;148:197–213. [cited 2017 Dec 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18087050
- Smith JB, Rosen J, Colbert A. Low serum testosterone in outpatient psychiatry clinics: addressing challenges to the screening and treatment of hypogonadism. Sex Med Rev [Internet]. 2017;[cited 2017 Dec 26]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2050052117301233
- Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract [Internet]. 2009;15:289–305. [cited 2017 Dec 26]. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00131746-200907000-00005
- Elliott J, Kelly SE, Millar AC, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open [Internet]. 2017;7:e015284. [cited 2017 Dec 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29150464
- McGinty HL, Phillips KM, Jim HSL, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer [Internet]. 2014;22:2271–2280. [cited 2017 Dec 26]. Available from: http://link.springer.com/10.1007/s00520-014-2285-1
- Lv W, Du N, Liu Y, et al. Low testosterone level and risk of Alzheimer’s disease in the elderly men: a systematic review and meta-analysis. Mol Neurobiol [Internet]. 2016;53:2679–2684. [cited 2017 Dec 26]. Available from: http://link.springer.com/10.1007/s12035-015-9315-y
- Wahjoepramono EJ, Asih PR, Aniwiyanti V, et al. The effects of testosterone supplementation on cognitive functioning in older men. CNS Neurol Disord Drug Targets [Internet]. 2016;15:337–343. [cited 2017 Dec 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26553159
- Xu L, Freeman G, Cowling BJ, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med [Internet]. 2013;11:108. [cited 2017 Aug 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23597181
- Basaria S, Harman SM, Travison TG, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels. JAMA [Internet]. 2015;314:570. [cited 2017 Aug 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26262795
- Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. Gong Y, editor. PLoS One [Internet]. 2014;9:e85805. [cited 2017 Aug 3].
- Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA [Internet]. 2013;310:1829–1836. [cited 2017 Aug 3].
- Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med [Internet]. 2010;363:109–122. [cited 2017 Dec 28]. DOI:10.1056/NEJMoa1000485.